Clinical trial NCT05371834: Microwave Treatment of Common and Plantar Warts
Official title: Pivotal Study to Assess the Clinical Efficacy and Safety of Microwave Treatment in Warts
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Warts
Keywords: HPV
Human Papilloma Virus
Swift System
Microwave
Verruca
Common warts
Plantar Warts
Cryotherapy
Lead sponsor: Blackwell Device Consulting
Sponsor class: INDUSTRY
Collaborators: name: Emblation Limited
First posted: 2022-05-12
Enrollment: 119
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multi-center, open, randomized, parallel-group, controlled, blind-assessed trial of approximately 124 subjects that require treatment for up to 5 common or plantar warts. Subjects will be randomized to one of two treatment groups: Microwave Treatment (Swift® system) or Cryotherapy.

Detailed description: The primary objective of this study is to collect evidence of the effectiveness of the Swift device for the treatment of common and plantar warts and compare with Cryotherapy.

The secondary objectives of this study are to collect evidence of the safety, effectiveness and patient experiences of the Swift device for the treatment of common and plantar warts and compare with Cryotherapy.

Eligible subjects who provide written informed consent will be randomized to either Microwave Treatment or Cryotherapy. Each eligible subject will receive treatment at the baseline visit (Visit 2) and again 4-weeks later. Subjects will receive a minimum of 2 treatments or, if further treatment is required, up to a maximum of 4 treatments; each treatment is given in 4-week intervals. Follow-up is 12-weeks after the last treatment has been administered where the warts will be assessed for resolution. Further follow-up visits occur 6-months and 12-months after the last treatment where the warts will be assessed for resolution or reoccurrence (if resolved at the 12-week visit).

Eligibility criteria: Inclusion Criteria:

1. Provision of signed and dated informed consent form;
2. Stated willingness to comply with all study procedures and availability for the duration of the study;
3. Age 18-64 years inclusive;
4. A minimum of one clinically significant common wart (usually found on hands, knees and elbows), or one plantar wart. Note: the warts for treatment cannot be a mixture of common and plantar warts;
5. Subject's common warts must measure between 3mm-10mm or for plantar warts, measure between 3mm-20mm, inclusive;
6. If currently receiving treatment for common or plantar warts, agree to stop their current medication for at least 28 days prior to the start of study treatment;
7. Agrees to refrain from using any other wart removal products or treatments during the study period;
8. Agrees to not take any non-steroidal anti-inflammatory drugs (NSAIDs) or antihistamines within a 12-hour period prior to and after randomized treatment;
9. Able to perform study assessments.

Exclusion Criteria:

1. Pregnancy or breast feeding;
2. Mosaic warts for treatment;
3. Warts (common or plantar) that have been reported by the subject as present for more than 5 years (relates to any wart present and which may not necessarily be treated in this study);
4. Warts for treatment on areas of thin or sensitive skin as determined by the Investigator, e.g., face, neck, armpits, breasts, buttocks or genitals;
5. Areas for treatment where the skin is irritated, reddened or showing any sign of inflammation (e.g. itching and swelling);
6. Warts for treatment with hair growth, birthmarks, dark moles, pigmented skin or any other unusual skin condition;
7. History of infection in designated treatment area within 90 days prior to first treatment;
8. Implantable Cardioverter Defibrillator (ICD), pacemaker or other implantable electronic devices;
9. Metal implants at site of treatment (within foot or ankle);
10. Known allergy or intolerance to microwave therapy and cryotherapy;
11. Unstable co-morbidities (cardiovascular disease, active malignancy, inflammatory arthritis);
12. Participating in another interventional study or have done so within the last 30-days;
13. Anticipated relocation or extensive travel outside of the local study area preventing compliance with study procedures;
14. Circulatory conditions affecting the acral areas - peripheral vascular disease, peripheral ischemia, vasculitis, Raynaud's, or related conditions;
15. Peripheral neuropathy;
16. Subject with known immunosuppression disorders through illness or medication (for example - corticosteroids, biologic agents, methotrexate, ciclosporin);
17. Subject with autoimmune disease;
18. Diabetes (Type I or II);
19. History of vascular interventions to the legs, deemed as an unacceptable risk by the Investigator;
20. Prior dissection of axillary lymph nodes (for treated hand) or inguinal lymph nodes (for treated feet);
21. Dependent lymphedema;
22. Congestive heart failure;
23. History of repeated cellulitis (2 or more episodes);
24. History of deep venous thrombosis;
25. Subject currently receiving prescribed blood thinning medication;
26. Subject who has ever had any topical metallic treatment (e.g, aluminum chloride, silver nitrate) within the past year.

Primary outcomes:
measure: Clearance of all treated warts, each of which is defined as "resolved" or "not resolved" based on the classification by the blinded site investigator assessing the treated warts at three months post final treatment (up to 5 warts in total).
timeFrame: 3 months post final treatment
Secondary outcomes:
measure: Clearance of all treated warts at three months post final treatment, each of which is defined as "lesion no longer visible" but assessed by the majority of three independent blinded assessors using photographs
timeFrame: 3 months post final treatment
measure: Efficacy of all warts classed as resolved by the blinded site investigator at three months post final treatment, by the number of warts treated
timeFrame: 3 months post final treatment
measure: Patient reported satisfaction with treatment at six and twelve months post final treatment
timeFrame: 6 and 12 months post final treatment
measure: Adverse events
timeFrame: 12 months post final treatment
measure: Change from baseline for size of treated warts at three months, six months and at twelve months post final treatment
timeFrame: 3 months, 6 months and 12 months post final treatment
measure: Patient reported pain score since last treatment at three, six and twelve months post final treatment
timeFrame: 3 months, 6 months and 12 months post final treatment
measure: Reoccurrence of any treated wart at six and twelve months post final treatment, as classified by the blinded site investigator and separately by photos reviewed by the majority of the three independent blinded assessors.
timeFrame: 6 months and 12 months post final treatment
measure: Clearance of all treated warts, each of which is defined as "resolved" or "not resolved" based on the classification by the blinded site investigator assessing the treated warts at six months and twelve months post final treatment.
timeFrame: 6 months and 12 months post final treatment
measure: The resolution rate for individual warts based on the classification by the blinded site investigator at 3 months post-final treatment.
timeFrame: 3 months post final treatment
Other outcomes:
Locations:
city: Miami
country: United States
facility: Miami Dermatology and Laser Institute
state: Florida
city: Palm Harbor
country: United States
facility: TrueBlue Clinical Research
state: Florida
city: Tampa
country: United States
facility: TrueBlue Clinical Research
state: Florida
city: Chicago
country: United States
facility: Weil Foot & Ankle Institute
state: Illinois
city: Naperville
country: United States
facility: Oak Dermatology
state: Illinois
city: Nashville
country: United States
facility: Tennessee Clinical Research Center
state: Tennessee
Study officials:
affiliation: Oak Dermatology
name: Dr Bhatia
role: PRINCIPAL_INVESTIGATOR
References: